Ronald van der Pluijm

Ronald van der Pluijm has extensive experience in startups, turnaround, multinational and ASX-listed corporate environments with a focus on the life science industry. He has a successful track record in building and growing operational companies through business development, partnerships and licensing and M&A resulting in strong sales and profit growth.

As chief executive for Australia and New Zealand at Actavis (now Allergen), Mr van der Plauijm successfully turned the business around and put it on the path to growth. He was part of the ASX-listed Psiron team (subsequently renamed Viralytics) which acquired the oncolytic immunotherapy, which was acquired by MSD in 2019 for $500 million.